Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...
and who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the unresectable or metastatic treatment ...
Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...
This important study advances our understanding of the way neurons in the auditory cortex of mice respond to unpredictable sounds. Through the use of state-of-the-art recording methods, compelling ...
Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®â–¼ (erdafitinib) as a monotherapy for the treatment ...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback